ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET FORECAST 2018-2026
KEY FINDINGS
The Asia Pacific ophthalmic drugs and devices market holds a high growth potential for the future owing to a large number of factors. These include rising geriatric population, rising investments in healthcare infrastructure and increasing prevalence of ocular diseases like disorders of both the cornea and the retina. By the end of the forecast period of 2018-2026, the market is expected to register a CAGR of 6.22%.
MARKET INSIGHTS
There has been an increasing trend of globalization in clinical research, with the shift of clinical activities to Asia Pacific region. The Asia-Pacific region has extremely assorted healthcare systems; each offering a diverse mix of public/private financing and delivery of medical services. The top five growth sectors in APAC include medical tourism, private medical insurance, and speciality hospitals. The China ophthalmic drugs and devices market captured the highest market share in 2017. Major factors which are driving the ophthalmic drug market in China include the rising geriatric population, increasing strategic moves such as investment, collaboration, and acquisition by key market players in the country, increasing prevalence of eye diseases, increasing healthcare expenditure to improve healthcare infrastructure, and the high life expectancy of individuals.
COMPETITIVE INSIGHTS
Market players like Pfizer, Sun Pharmaceuticals Industries Ltd, Santen Pharmaceutical Co Ltd, Carl Zeiss Ag, GlaxoSmithKline, Novartis International Ag, Valent Pharmaceuticals International Inc, Johnson & Johnson Inc, Allergan Inc, Roche Holding Ag, Bayer, and Ziemer Group Holding Ag are competing in this market.
The Asia Pacific ophthalmic drugs and devices market holds a high growth potential for the future owing to a large number of factors. These include rising geriatric population, rising investments in healthcare infrastructure and increasing prevalence of ocular diseases like disorders of both the cornea and the retina. By the end of the forecast period of 2018-2026, the market is expected to register a CAGR of 6.22%.
MARKET INSIGHTS
There has been an increasing trend of globalization in clinical research, with the shift of clinical activities to Asia Pacific region. The Asia-Pacific region has extremely assorted healthcare systems; each offering a diverse mix of public/private financing and delivery of medical services. The top five growth sectors in APAC include medical tourism, private medical insurance, and speciality hospitals. The China ophthalmic drugs and devices market captured the highest market share in 2017. Major factors which are driving the ophthalmic drug market in China include the rising geriatric population, increasing strategic moves such as investment, collaboration, and acquisition by key market players in the country, increasing prevalence of eye diseases, increasing healthcare expenditure to improve healthcare infrastructure, and the high life expectancy of individuals.
COMPETITIVE INSIGHTS
Market players like Pfizer, Sun Pharmaceuticals Industries Ltd, Santen Pharmaceutical Co Ltd, Carl Zeiss Ag, GlaxoSmithKline, Novartis International Ag, Valent Pharmaceuticals International Inc, Johnson & Johnson Inc, Allergan Inc, Roche Holding Ag, Bayer, and Ziemer Group Holding Ag are competing in this market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.3. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING PREVALENCE OF DIABETES INCREASES THE PROBABILITY OF OPHTHALMIC DISORDERS
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. KEY BUYING CRITERIA
6.3.1. COST
6.3.2. EFFICACY
6.3.3. ACCESSIBILITY
6.3.4. INNOVATION
6.4. SUPPLY CHAIN ANALYSIS
6.4.1. SUPPLIERS
6.4.2. MANUFACTURERS
6.4.3. DISTRIBUTORS AND RETAILERS
6.4.4. END USERS
6.5. REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. INDIA
7.1.2. CHINA
7.1.3. JAPAN
7.1.4. SOUTH KOREA
7.1.5. AUSTRALIA
7.1.6. REST OF APAC
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 4 EYE DRUGS GONE OFF-PATENT
TABLE 5 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 6 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 7 ASIA PACIFIC DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 8 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS 2018-2026 ($ MILLION)
TABLE 10 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET 2018-2026 ($ MILLION)
TABLE 11 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES 2018-2026 ($ MILLION)
TABLE 12 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE 2018-2026 ($ MILLION)
TABLE 13 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER 2018-2026 ($ MILLION)
TABLE 14 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS 2018-2026 ($ MILLION)
TABLE 15 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER 2018-2026 ($ MILLION)
TABLE 16 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER 2018-2026 ($ MILLION)
TABLE 17 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE 2018-2026 ($ MILLION)
TABLE 18 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS 2018-2026 ($ MILLION)
TABLE 19 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2018-2026 ($ MILLION)
TABLE 20 ASIA PACIFIC DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 21 ASIA PACIFIC SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 22 ASIA PACIFIC SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 23 ASIA PACIFIC SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 24 ASIA PACIFIC SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 25 ASIA PACIFIC DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
TABLE 26 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 27 ASIA PACIFIC DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
TABLE 28 ASIA PACIFIC DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
TABLE 29 ASIA PACIFIC DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
TABLE 30 ASIA PACIFIC DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
TABLE 31 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
FIGURE 2 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 3 ASIA PACIFIC DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 4 ASIA PACIFIC DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 5 ASIA PACIFIC DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 6 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 7 ASIA PACIFIC DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 8 ASIA PACIFIC DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 9 ASIA PACIFIC DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 10 ASIA PACIFIC DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 11 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 12 INDIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 13 CHINA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 14 JAPAN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 15 SOUTH KOREA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 16 AUSTRALIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 17 REST OF APAC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 18 OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 19 OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.3. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING PREVALENCE OF DIABETES INCREASES THE PROBABILITY OF OPHTHALMIC DISORDERS
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. KEY BUYING CRITERIA
6.3.1. COST
6.3.2. EFFICACY
6.3.3. ACCESSIBILITY
6.3.4. INNOVATION
6.4. SUPPLY CHAIN ANALYSIS
6.4.1. SUPPLIERS
6.4.2. MANUFACTURERS
6.4.3. DISTRIBUTORS AND RETAILERS
6.4.4. END USERS
6.5. REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. INDIA
7.1.2. CHINA
7.1.3. JAPAN
7.1.4. SOUTH KOREA
7.1.5. AUSTRALIA
7.1.6. REST OF APAC
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 4 EYE DRUGS GONE OFF-PATENT
TABLE 5 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 6 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 7 ASIA PACIFIC DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 8 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS 2018-2026 ($ MILLION)
TABLE 10 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET 2018-2026 ($ MILLION)
TABLE 11 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES 2018-2026 ($ MILLION)
TABLE 12 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE 2018-2026 ($ MILLION)
TABLE 13 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER 2018-2026 ($ MILLION)
TABLE 14 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS 2018-2026 ($ MILLION)
TABLE 15 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER 2018-2026 ($ MILLION)
TABLE 16 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER 2018-2026 ($ MILLION)
TABLE 17 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE 2018-2026 ($ MILLION)
TABLE 18 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS 2018-2026 ($ MILLION)
TABLE 19 ASIA PACIFIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2018-2026 ($ MILLION)
TABLE 20 ASIA PACIFIC DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 21 ASIA PACIFIC SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 22 ASIA PACIFIC SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 23 ASIA PACIFIC SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 24 ASIA PACIFIC SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 25 ASIA PACIFIC DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
TABLE 26 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 27 ASIA PACIFIC DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
TABLE 28 ASIA PACIFIC DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
TABLE 29 ASIA PACIFIC DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
TABLE 30 ASIA PACIFIC DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
TABLE 31 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
FIGURE 2 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 3 ASIA PACIFIC DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 4 ASIA PACIFIC DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 5 ASIA PACIFIC DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 6 ASIA PACIFIC DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 7 ASIA PACIFIC DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 8 ASIA PACIFIC DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 9 ASIA PACIFIC DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 10 ASIA PACIFIC DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 11 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 12 INDIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 13 CHINA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 14 JAPAN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 15 SOUTH KOREA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 16 AUSTRALIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 17 REST OF APAC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 18 OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 19 OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
